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I. INTRODUCTION 
Pharmaceutical manufacturers have advertised prescription drug products to the 
public for over a decade. These consumer-directed advertisements often are promoted, 
like those for other consumer products, with appeals to vanity, insecurity, and pain. 
Prescription drug advertisements possess certain unique features, most notably a state-
ment that consumers must visit their doctor before purchasing the product. These ad-
vertisements also encourage consumers to obtain more detailed information from the 
manufacturer, often by using 800 numbers to phone in requests for free video tapes, 
brochures, and information packets. 
Depo-Provera is one of these prescription _drugs. Since the Food and Drug Admin-
istration (FDA) approved the three-month injectable contraceptive in October 1992, 
Upjohn, the drug's manufacturer, has marketed the drug widely.1 The Depo-Provera 
advertisement provides the opportunity to explore several questions about prescription 
drug advertising. Does the FDA have the authority to regulate consumer-oriented pre-
scription drug advertising? If the agency has the authority to protect consumers against 
deceptive advertisements, do the Depo-Provera advertisements fairly represent the 
contraceptive's risks and benefits? If the advertisements produce a more informed con-
sumer, do they expose Upjohn to product liability? If they do, will the company be able 
to successfully defend itself by employing the learned intermediary rule and the federal 
doctrine of preemption? If Upjohn is unable to rely upon these defenses, what are the 
product liability consequences of its Depo-Provera advertisement? These questions 
generally address the FDA's authority, Upjohn's liability, and the consequences for women 
who choose an elective drug. Initially, the answers are defined by the parameters of, and 
controversy over, a pharmaceutical risk regulation system in which federal and state 
laws govern public availability and individual use of prescription drugs. 
The FDA, drug companies, physicians, and patients are responsible for regulating 
pharmaceutical risk. But patients find it difficult to make an informed decision about 
using a prescription drug because the FDA, drug companies, and physicians are not 
members of an integrated system of risk regulation, but are participants whose involve-
ment in defining risk is structured by the Federal Food, Drug, and Cosmetic Act (FDCA),2 
by state tort law, and ultimately by the federal Constitution. These laws create the frame-
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1 See, e.g., Michael Klitsch, Injectable Hormones and Regulatory Controversy: An End to the Long-
Running Story?, 25 FAMILY PlANNiNG PERsPECTIVES 37 (1993); and William Green, The Odyssey of Depo-
Provera, 42 Fooo DRUG COSM. L.J. 567 (1987). 
2 Pub. L. No. 75-717, 52 Stat. 1040 (1938), as amended 21 U.S.C. §§ 301 et seq. (1988). 
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work for a dual system of regulation and two levels of risk management. 3 
Whether drugs should be made publicly available, the first level of risk regulation, 
is the legal responsibility of the FDA. The agency manages this risk through its control 
over experimental drug research and drug marketing. This control includes its authority 
to approve a drug's package insert, which is the official labeling that describes the 
drug's approved uses, warnings, precautions, side effects, and contraindications. 
The second level of risk regulation, which asks whether the drug should be used by 
an individual, is the responsibility of physicians who decide to prescribe a drug for 
patient use based on medical knowledge of the patient and the drug. A physician's 
knowledge of a drug may be based on the drug's FDA-approved labeling, but FDA 
authority does not extend to physician prescription practices.4 If a physician fails to 
regulate prescription drug risk, the patient's recourse is governed by state medical mal-
practice law. 
Unlike those of physicians, pharmaceutical company risk regulation practices are 
governed by both federal and state law. Drug companies are required to comply with 
the FDA's labeling regulations, changes in the labeling of previously approved drugs, 
and orders to remove drugs from the market. Drug companies are also required to com-
ply with FDA regulation of their marketing practic{:s, including advertising, and to no-
tify the agency about adverse reactions to their drugs. At the same time, pharmaceutical 
companies are bound by state product liability law, which entitles patients to claim that 
a drug's manufacturer failed to warn a physician about the drug's risks and that this 
failure to warn caused them injury. 
This article will explore the personal consequences of this dual system of risk regu-
lation for a woman who reads the Depo-Provera advertisement, consults with her phy-
sician and receives an injection. Part II will analyze the advertisement and its compli-
ance with FDA regulations. Part ill will explore the product liability consequences of 
the Depo-Provera advertisement. Here attention will focus on a hypothetical case based 
on Up john v. MacMurdo, 5 and the ability of Upjohn to avoid liability by relying on the 
learned intermediary rule and the federal constitutional doctrine of preemption. 
n. THE DEro-PRovERA ADvERTisEMENT 
The FDA relies on the 1962 amendments to the FDCA6 to regulate prescription 
drug advertising. Section 502(n) of the Amendments contains the "brief summary" re-
quirement, which provides that a prescription drug is misbranded unless its advertise-
ments contain "information in a brief summary relating to side effects, contraindications, 
and effectiveness as shall be required in [FDA] regulations."' Section 502(n)'s require-
ment was enacted to better inform physicians about prescription drugs, not to protect 
consumers against deceptive advertising.8 In the early 1980s, pharmaceutical compa-
nies began to advertise their prescription drug products directly to the general public. 
The FDA responded in 1985 by extending its section 502(n) authority "to regulate 
3 See Henry Grabowski, Product Uability in Pharmaceuticals, in THE LIABIUTY MAZE 360-66 (Peter 
W. Huber & Roben E. Litan, eds. 1991). 
• See 37 Fed. Reg. 16,503 (1972). 
5 562 So. 680, 681-82 (Fla. 1990). 
6 Pub. L. No. 87-781, 76 Stat. 780 (1962). 
7 21 U.S.C. §§ 352(n). 
8 See infra note 56. 
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prescription drug advertising, regardless of its intended audience."9 
Pharmaceutical advertisements for prescription drugs aimed at the general public 
have raised questions about the new duties manufacturers may assume under state prod-
uct liability law.10 Do the advertisements resemble those for other products? Do they 
fairly represent the drug's risks and benefits? Do they comply with section 502(n)'s 
brief summary requirement? Are the company's promotional claims limited to those 
approved in the labeling? Are the virtues of the product stated in bold print? Are the 
warnings contained in the advertisement, and, if so, are they prominent and easy to 
understand or are they in technical language and small print? If the warnings appear on 
subsequent pages, are there references in the advertisement to these pages? Do the 
warnings comply with section 502(n)'s brief summary requirement? Do the advertise-
ments encourage women to seek additional product information from the manufac-
turer? Do the advertisements tell consumers to visit their doctor in order to purchase the 
product? These questions frame the following analysis of the Depo-Provera advertise-
ment, its accompanying patient information, and its 800 number information. 
A. The Advertisement 
Upjohn's multi-page advertisement for Depo-Provera has appeared in major na-
tional news, health, and women's magazines. 11 Overall, the advertisement employs the 
distinctive features of prescription drug advertisements. The first page introduces the 
product's basic appeal to convenience. In deep pink and mauve tones is a wristwatch 
with months characteristic of the four seasons printed on the face: March at 3:00, June 
at 6:00, September at 9:00, and December at 12:00. On the second page, this soothing 
image is transformed into a clear statement of the drug's basic appeal. In large print at 
the top of the page, the advertisement announces, "Introducing Birth Control You Think 
About Just 4 Times a Year." The corollary appeal appears in smaller print immediately 
below, saying "Many women wish they didn't have to remember their birth control 
every day." After this generic comparison with the contraceptive pill, the advertisement 
directly addresses the potential consumers, saying "If you're one of them, you might 
want to know about Depo-Provera." Thereafter, the advertisement has three major themes 
that roughly mirror the drug's FDA labeling: its benefits, side effects, and 
contraindications. 
The description ofDepo-Provera's benefits begins by repeating the advertisement's 
9 50 Fed. Reg. 36,667 (1985). 
10 See, e.g., Nancy L. Buc, Current Regulatory Issues in Marketing Prescription Drugs: Comparative 
Claims and Advertising to Consumers, 37 FooD DRuG CosM. L.J. 402 (1982); Mark Novitch, Direct to 
Consumer Advertising of Prescription Drugs, 39 FooD DRuG CosM. L.J. 306 (1984); Paul Rheingold, Ex-
panding liability of the Drug Manufacturer to the Consumer, 40 FooD DRUG CosM. L.J. 135 (1985); Elisabeth 
Rosenthal, Drug Makers Set Off a Bitter Debate With Ads Aimed Directly at Patients, N.Y. TIMES, Mar. 3, 
1991, at 17; and Lance Gilgore, A Consideration of Direct-to-Consumer Advertising of Prescription Drugs 
and Potential Legal Problems With the Brief Summary: Is the FDA's Regulatory Authority Illusory?, 46 
Fooo DRUG CosM. L.J. 849 (1991). 
11 The Upjohn Company, "Introducing Birth Control You Think About Just 4 Times a Year'' (1993) 
(Depo-Provera consumer-directed advertisement). 
Variations on the Depo-Provera advertisement make similar appeals to convenience. A recent one and 
a half-page advertisement in Woman's Day magazine features a mother and her three children. On the 
picture is printed the basic appeal: "With three kids, who has time to think? So I picked birth control I only 
have to think about 4 times a year." WoMAN's DAY, Feb. 1, 1995. The remaining half page contains the text 
of the advertisement. Aside from these variations in visual appeals to convenience, the texts of the adver-
tisements appear to contain only minor nonsubstantive differences. 
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appeal to convenience, linking it to physician availability and emphasizing the drug's 
reliability, informs the reader that since the drug is 99% effective in preventing concep-
tion it is "one of the most reliable contraceptives available." Safety is addressed tangen-
tially by presenting a positive image of the drug's worldwide use. The advertisement 
notes the product's lengthy use by "millions of women" in Western European nations 
"like England, France, and Sweden," which have a major commitment to personal health, 
but does not mention that the drug's most extensive use includes millions of women in 
Third World nations like Kenya, India, Thailand, Chile, and Costa Rica. Then the ad-
vertisement turns to Depo-Provera's reversibility, saying that a woman "can usually 
become pregnant" once she stops taking the drug, but does not mention that a woman's 
return to fertility can vary from six to eighteen months. Cost, the final benefit described 
in the advertisement, is said to be "about the same per year as birth control pills." This 
rather generic comparison, although accurate, may leave the impression that a woman 
would be well advised to choose Depo-Provera for convenience or economic reasons, 
but obscures the fact that the higher payment for each individual injection of Depo-
Provera might be beyond the means of a lower income woman. 
The advertisement identifies four side effects in declining order of importance: 
menstrual bleeding, weight gain, amenorrhea, and osteoporosis. The advertisement notes 
that "most" women who use Depo-Provera experience irregular, unpredictable men-
strual bleeding and weight gain; ''many women stop having monthly periods;" and some 
"may" experience "a decrease in the amount of minerals stored in ... [their] bones." 
None of these side effects is described as serious. Women are told that amenorrhea is 
"not a medical problem,"12 but they are not informed that weight gain and the likelihood 
of the drug causing osteoporosis is doubly qualified. 13 Women are told in the advertise-
ment not to be concerned about irregular and unpredictable menstrual bleeding, but 
they are not informed about a major finding of a study by Upjohn researchers, Drs. Paul 
Schwallie and J. Robert Assenzo, that the drug's use causes prolonged menstrual bleed-
ing.I4 
Under the heading "Depo-Provera is· not right for every woman," the advertise-
ment clearly describes four of Depo-Provera's contraindications: "Women with a fam-
ily or personal history of breast cancer, blood clots, liver disease, or those who think 
they might be pregnant, should not use Depo-Provera." The advertisement also makes 
it clear from the outset that Depo-Provera is available only through a physician. There-
after, it emphasizes four times the need to discuss contraceptive "risks and benefits" 
with a physician. At the bottom of the advertisement, however, its reference to the 
accompanying patient information and the need to discuss it with a physician appears in 
very small print. 
B. The Patient Information 
"Depo-Provera Contraceptive Injection," the patient information statement, ap-
11 /d. The advertisement states: "Your doctor can explain why this happens and that it is not a medical 
problem." 
13 /d. The advertisement states: "Use of Depo-Provera may be associated with a decrease in the amount 
of minerals stored in your bones, which may be considered among the risk factors for development of 
osteoporosis." (emphasis added). 
•• Paul Schwallie & J. Robert Assenzo, Contraceptive Use: Efficacy Study Utilizing 
Medroxyprogesterone Acetate Administered as an Intramuscular Injection Once Every Ninety Days" 24 
FERTIUTY AND STERILITY 331, 334 (1973). 
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pears on the page following the advertisement. 15 Largely based on the drug's FDA-
approved labeling, its format is reader-friendly; its nine bold-type headings speak di-
rectly to a woman in a question-and-answer format; and under its numbered subhead-
ings, it details in small print the drug's common risks, possible side effects, and precau-
tions in neither overly complicated nor technical language. A woman is advised to con-
sult her health provider in making a contraceptive choice, and, after using Depo-Provera, 
if she suspects she is pregnant, misses a period, or experiences the specified side ef-
fects. 
Menstrual bleeding is mentioned specifically in the patient information statement 
under three headings: under "What are the Possible Side Effects of Depo-Provera?" it 
states that "some women reported ... [i]rregular menstrual bleeding" in clinical trials; 
under "What Symptoms May Signal Problems While Using Depo-Provera?" it lists 
unusually heavy vaginal bleeding; and under "What are the Risks of Using Depo-
Provera?" it mentions unusually heavy or continuous bleeding, but asserts (without any 
reference to research findings) that this is "not a usual effect ofDepo-Provera." In all 
three instances, a woman is told explicitly to call or see her health care provider, but she 
is not told about a major finding from the Schwallie and Assenzo study: 26.9% of 
women who received their first Depo-Provera injection experienced excessive bleed-
ing, i.e., bleeding and/or spotting from twelve to thirty days per month for three months. 16 
C. The 800 Number Information 
The Depo-Provera advertisement encourages women who want more information 
to call an 800 number. This information includes a copy of the patient labeling and two 
brochures, one on Depo-Provera and one comparing methods of birth control. The 
patient labeling adds little to a woman's knowledge about Depo-Provera, because it is 
only a slightly reconfigured version of the patient information accompanying the adver-
tisement.17 The Depo-Provera brochure, which is based on the advertisement's format 
and appeal, provides more information than the advertisement about the drug and its 
benefits, side effects, and contraindications. 18 The brochure also provides new informa-
tion on the painfulness of the injection, the importance of receiving timely injections, 
and the need for additional protection against sexually transmitted diseases. The bro-
chure does not contain any more information about the menstrual bleeding side effect 
than the advertisement. The brochure on "Choosing a Birth Control Method," which 
briefly describes and compares barrier methods, the intrauterine device (IUD), the Pill, 
Norplant, and Depo-Provera, 19 is meant to be read in conjunction with the back page of 
the Depo-Provera brochure that advises a woman to talk with her physician about birth 
control methods, and concludes with the suggestion that it is the woman who chooses: 
"Once you have all the information you need, you will be able to make the choice which 
15 The Upjohn Company, Depo-Provera Contraceptive Injection (1993) (patient information included 
with Depo-Provera consumer advertisement). 
16 See supra note 14. 
17 The Upjohn Company, Depo-Provera Contraceptive Injection, Patient Labeling (1993) (patient 
labeling included with the two Depo-Provera 800 number brochures). 
18 The Upjohn Company, Contraceptive Confidence 3 Months at a 1ime, (1993) (Depo-Provera 800 
number brochure). 
19 Association for Reproductive Health Professionals, Choosing a Birth Control Method (Jan. 1994) 
(800 number brochure briefly describing and comparing the average success rate, length of protection, 
average cost, return to fertility, privacy of use, and protection against sexually transmitted diseases of bar-
rier methods, the IUD, the Pill, Norplant, and Depo-Provera). 
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is best for you." 
D. Summary 
The Depo-Provera advertisement, given its subtle tone and serious character, does 
not resemble advertisements for other consumer products, other than in its appeal to 
convenience. The advertisement and its accompanying patient information and 800 
number materials may comply with section 502's brief summary requirement. The issue 
here is whether the advertisement, because it is aimed at the general public, creates new 
duties for Upjohn under state product liability law. 
ill. THE DEPO-PROVERA ADVERTISEMENT'S PRODUCT LIABILITY 
CoNSEQUENCES 
Once the FDA has approved a drug, the agency has answered one part of the risk 
regulation equation: whether the drug should be made publicly available. The other part 
of the equation is whether the drug should be used by a particular patient. This decision 
turns, in part, on a physician's knowledge of the drug and its FDA-approved labeling. If 
a patient believes that a pharmaceutical company has failed to warn a physician about 
the drug's risks, and she has suffered harm as a result, the patient may initiate a product 
liability claim against the manufacturer. In a product liability case, attention will focus 
on the drug's labeling and the issue will be whether the label information was adequate 
to warn the consumer about the risks inherent in the drug and the harm that could follow 
from its use.20 
The Depo-Provera advertisement has the potential for generating a wide array of 
product liability actions. This analysis will not examine this world of potential litiga-
tion, but will focus on one major short-term side effect not sufficiently identified in the 
advertisement: heavy and prolonged menstrual bleeding. It will first examine Up john v. 
MacMurdo,21 the leading product liability case on this issue prior to the drug's contra-
ceptive approval. Then, the article will consider a hypothetical case based on MacMurdo 
and the drug's advertisement, will explore two defenses drug manufacturers frequently 
raise - the learned intermediary rule and federal preemption doctrine - , and will 
conclude with an evaluation ofUpjohn's potential liability for the advertisement's warning 
about menstrual bleeding. 
A. Upjohn v. MacMurdo 
Depo-Provera's use as an unapproved contraceptive was the subject of medical 
malpractice and product liability suits in the quarter century prior to its approval in 
1992. Women who experienced a variety of debilitating short-term side effects from 
using the drug sued their physicians and Upjohn, but their cases were dismissed or 
settled. Only Anne MacMurdo's product liability case was tried, appealed, and reviewed 
by a state supreme court.22 Anne MacMurdo received two injections of Depo-Provera 
20 Lars Noah, The Imperative to Warn: Disentangling the "Right to Know" from the "Need to Know" 
About Consumer Products Hazards," 11 YALE J. REG. 293, 326-32 (1994). 
21 562 So. 680 (Fla. 1990). 
22 See William Green, Miscarriage of Justice: Depo-Provera Case May Insulate Drug Makers, 27 
TRIAL 61 (1991). 
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in 1974. The injections produced heavy and prolonged menstrual bleeding, which her 
obstetrician ended by performing a hysterectomy. At trial in 1986, MacMurdo's attor-
ney argued that the Depo-Provera package insert had failed to warn her physician that 
the use of the drug could produce excessive and prolonged bleeding. The trial court 
jury found that Upjohn had been negligent in failing to provide adequate package insert 
warnings.23 An intermediate appellate court affirmed the trial court's finding that "there 
was ... substantial evidence presented that the drug ... caused MacMurdo's bleeding 
problems, that the warnings were insufficient to alert her physician of this risk, and that 
her hysterectomy was performed to treat the bleeding condition."24 
On appeal, the Florida Supreme Court held that the adequacy of drug warnings was 
governed by Felix v. Hoffmann-La Roche, Inc.,23 which had held that the adequacy of a 
manufacturer's warning about the dangers of a drug is often "a question offact, ... [but] 
it can become a question of law where the warning is accurate, clear, and unambigu-
ous."26 Applying the Felix standard, the MacMurdo court held that because package 
insert warnings were directed at physicians, their adequacy to inform had to be proven 
by expert testimony. After rejecting the plaintiff's expert because he was a Ph.D. phar-
macologist, and selectively using the obstetrician's testimony, the court concluded that 
"[n]o medical expert testified that the package insert was insufficient to put a doctor on 
notice that the symptoms displayed by MacMurdo ... could result from the use of 
Depo-Provera."27 As a consequence, the claim that the Depo-Provera package insert 
failed to warn against prolonged bleeding was held insufficient to present a jury ques-
tion. Because "the insert [had] warned of the possibility of abnormal bleeding outside 
the menstrual period," the court held that these warnings, in light of Felix, were accu-
rate, clear, and unambiguous as a matter of law. 28 
B. A Hypothetical Depo-Provera Product Liability Case 
Suppose that after the product's approval another Anne MacMurdo read the Depo-
Provera advertisement, including the accompanying patient information and 800 num-
ber materials, visited her doctor and discussed the risks and benefits of birth control 
options, and chose Depo-Provera. Suppose that her doctor, who may have read the 
physician advertising material on Depo-Provera,29 consulted the Physicians' Desk Ref-
erence (PDR) entry on the drug,30 gave her a physical examination, and then an injec-
tion. Subsequently, the patient experienced prolonged menstrual bleeding, which was 
23 MacMurdo v. Upjohn, No. 78-8497 CL (Broward Cir. Ct. Aa. 1986). 
2A Upjohn v. MacMurdo, 536 S.2d 337, 339-40 (Aa. Dist. Ct. App. 1988). 
25 Upjohn v. MacMurdo, 562 So. at 681-82, citing Felix v. Hoffmann-La Roche, Inc., 540 So.2d 102 
(Aa 1989). 
26 Felix, 540 So.2d at lOS. 
7.1 Id. 
20 Id. 
29 The Upjohn Company, Depo-Provera Contraceptive Injection. Contraceptive Confidence 3 Months 
at a Time, 18 THE FEMALE PATIENT (Nov. 1993). Physician information is included with the Depo-Provera 
physician advertisement. The Upjohn Company, We'll Help Her Learn About the First 3-Month Contra-
ceptive. You'll Help Her Decide, 18 THE FEMALE PATIENT (Nov. 1993). 
Two recent full-page health care provider and physician-directed advertisements titled "Contraceptive 
Confidence 3 Months at a Time" feature the wristwatch picture in deep pink and mauve tones. In very small 
print at the bottom of the page, the advertisement identifies two contraindications and requests the reader to 
"[p]lease see [the] brief summary of prescribing information on [the] adjacent page." 27 FAMILY PLANNING 
PERsPECilVES (Mar./ Apr. 1995) and 86 0BS"reTIUCS AND GYNECOLOGY (Aug. 1995). 
30 PHYSICIANS' DESK REFERENCE, Depo-Provera Contraceptive Injection 2543-46 (49th ed. 1995). 
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terminated by a hysterectomy. 
Suppose that this hypothetical woman sued Upjohn, claiming that the drug's con-
sumer and physician-oriented advertising materials and the PDR were inadequate to 
infonn her and her physician that heavy and prolonged menstrual bleeding was a likely 
side effect from the drug's use, because Upjohn, knowing the results of the Schwallie 
and Assenzo study, included it in the PDR list of references, but failed to provide in the 
PDR and the physician's and consumer-oriented advertising material a major finding of 
the Schwallie and Assenzo study: 26.9% of women bled from twelve to thirty days per 
month during the first three months of drug use. 31 
Suppose finally that this hypothetical physician, like Anne MacMurdo's, testified 
at trial that when the woman complained of abnormal bleeding, he did not consider that 
Depo-Provera was causing her problem because the PDR identified it as an unusual or 
rare side effect. Given these suppositions, would the legal outcome be different than the 
one in Anne MacMurdo's case? The answer would likely depend on the applicability of 
the learned intennediary rule, the doctrine of preemption, and the state product liability 
law to consumer-oriented prescription drug advertisements. 
C. Learned Intermediary Defense 
If a woman brought a product liability action claiming the Depo-Provera advertise-
ment failed adequately to warn her against heavy and prolonged menstrual bleeding, 
Upjohn would be likely to raise a learned intennediary defense. State and federal courts 
first recognized the learned intennediary rule in the 1966 case of Sterling Drug, Inc. v. 
Cornish.32 The rule protects drug manufacturers if they "direct their warnings to pre-
scribing physicians who, in tum, are expected to serve as 'learned intennediaries' for 
the manufacturer and provide the necessary warnings to their patients."33 Subsequently, 
the FDA challenged the assumptions of the learned intennediary rule when it required 
patient inserts for oral contraceptives in 1970 and IUDs in 1975.34 Some courts have 
recognized exceptions to the learned intennediary rule in cases involving contracep-
tives, but the contraceptive exception is limited to the Pill and IUD. So far, state and 
federal courts have been unwilling to create an exception for advertising. Would the 
courts extend the contraceptive exception to include Depo-Provera? Are these courts 
likely to recognize a learned intennediary exception for advertising prescription drugs, 
including Depo-Provera? 
Judicial recognition of an exception for the Pill and IUD cases could be expanded 
to support an exception for Depo-Provera. A court relying on Stephens v. G. D. Searle & 
Co. 3s and Hill v. Searle l.Aboratories,36 two cases that recognized exceptions for the 
contraceptive pill and IUD, could reject the learned intennediary rule in a case involv-
ing the injectable drug. A court could reason that women who receive an injection of 
31 See supra note 14. The Schwallie and Assenza study also found that, after the second injection, 
20.5% of the women continued to experience bleeding from eleven days to every day per month during the 
second three months. 
32 370 F.2d 82 (8th Cir. 1966). 
33 Teresa M. Schwartz, Consumer-Directed Prescription Drug Advertising and the Learned Interme-
diary Rule, 46 Fooo DRUG COSM. L.J. 829 (1991). 
34 See, e.g., Teresa M. Schwartz, Consumer Warnings for Oral Contraceptives: A New Exception to 
the Prescription Drug Rule, 41 Fooo DRUG CosM. L.J. 241 (1986); and Howard Rowe, Patient Package 
lnsens: The Proper Prescription?, 50 Fooo AND DRUG L.J. 95 (1987). 
3' 602 F. Supp. 379 (E.D. Mich. 1985). 
36 884 F.2d I 064 (8th Cir. 1989). 
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Depo-Provera, like those who receive the Pill and IUD, are more likely to have decided 
to use that birth control method before visiting their physician, and will have only infre-
quent contact with a physician over a long period of time (three months) after receiving 
the injection. A court also could reason that Depo-Provera, like the Pill and IUD, has 
serious side effects, that FDA regulations require its manufacturer to provide direct 
warnings to patients by means of patient package inserts, and that the drug is marketed 
directly to patients. Taken together, these factors that distinguish contraceptives from 
other prescription drugs could be made applicable to Depo-Provera. 
The Stephens and Hill cases also suggest that Depo-Provera might qualify for a 
consumer-directed advertising exception, but it is less likely that a court would recog-
nize this exception. A key question would be whether the court believes that the Depo-
Provera advertisement has "significantly affected the nature of the doctor/patient rela-
tionship."37 A woman who reads the advertisement is told that her doctor is the princi-
pal source of medical information about the drug. The advertisement states that "before 
... you consider any birth control method, you should discuss the risks and benefits 
with your physician."38 The advertisement also encourages the woman, albeit in very 
small print at the bottom of the page, to discuss the accompanying patient information 
with her doctor. 
The patient information emphasizes that her physician is the learned medical inter-
mediary who "will help you compare Depo-Provera with other contraceptive methods 
and give you the information you need in order to decide which contraceptive method is 
the right choice for you."39 The patient information also tells the woman to inform her 
doctor about medications she is taking and her personal and family medical history 
related to use of the drug. Finally, the Depo-Provera 800 number brochure, after advis-
ing a woman to talk with her physician about birth control methods, states that it is she 
who chooses: "Once you have all the information you need, you will be able to make the 
choice which is best for you. "40 
The Depo-Provera advertisement clearly encourages a woman to play an active 
role in making a contraceptive decision. Has this advertisement thereby altered the 
doctor-patient relationship sufficiently to create an advertising exception? Some courts 
would be unpersuaded if they "consider[ed] only one issue- whether a doctor pre-
scribed the product for the patient- and ignore[ d) other circumstances such as the 
nature of the product and whether the patient is actively involved in choosing the prod-
uct."41 Other courts may be persuaded by the decisions in Hensigen v. Bloomfield Mo-
tors42 that "a manufacturer's duty runs directly to the consumer when it markets prod-
ucts directly to the consumer;"43 Stephens v. Parke-Davis44 that heavily advertised pre-
scription drugs (i.e., those that are overpromoted to physicians) rendered FDA-approved 
warnings inadequate; and by Stephens and Hill, that abandoned the learned intermedi-
ary rule, in part because the drug manufacturers had aimed their advertising directly at 
the public. For these courts, the issue would not be who writes the prescription, but who 
decides to take the drug. If that decision is made by a patient, largely on the basis of 
37 See Schwartz, supra note 33, at 839. 
38 See supra note 11. 
39 See supra note 15. 
40 See supra note 18. 
41 See Schwartz, supra note 33, at 840. 
42 161 A.2d 69 (N.J. 1960). 
43 See Schwartz, supra note 33, at 841. 
.. 507 P.2d 653 (Cal. 1973). 
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Upjohn's patient-directed Depo-Provera advertisement, before she visits her doctor, 
these courts would be likely to conclude that any conversation she had with her doctor 
about risks and benefits of contraceptive methods was merely a formulaic exercise for 
her to receive the injection. 
D. Preemption 
Upjohn would have another defense against a state product liability suit if a court 
extended the contraceptive exception or recognized an advertising exception to exempt 
Depo-Provera from the learned intermediary rule. The drug company could argue that 
recovery under a product liability theory is preempted by its compliance with the brief 
summary requirement of section 502(n) of the FDCA.45 Federal law may override state 
law if a congressional statute expressly preempts state law, "if the statute impliedly pre-
empts state law by establishing a pervasive regulatory scheme that occupies the entire 
field, and if the state law, although it is neither expressly nor impliedly preempted, 
actually conflicts with the statute.46 
Since Upjohn would have to concede that the FDCA does not expressly preempt 
state tort law, including a product liability cause..of action,47 the drug manufacturer 
would have to base its preemption arguments on implied occupation of the field and 
actual conflict theories.48 Even so, Upjohn in this case would face an "uphill battle."49 
As the Supreme Court observed in Hillsborough County v. Automated Medical Labo-
ratories, 50 Upjohn would have to demonstrate that its compliance with section 502(n) 
was strong enough to overcome the presumption that state product liability suits based 
on the manufacturer's consumer-directed advertising could "constitutionally co-exist 
with federal regulation."51 In fact, Abbott Laboratories v. American CyanamicfS2 and 
Mazur v. Merc~3 emphasized that the "presumption against preemption is even stron-
ger when state regulation of matters related to health and safety are involved and when 
federal regulation would work to preempt state tort law remedies."54 These federal courts 
would not be disposed to find preemption ifUpjohn's compliance with section 502(n) 
would enfeeble a state's ability to protect its people from the dangers of contraceptive 
use and leave women harmed by Depo-Provera without a remedy at law. 
Upjohn may argue that the FDA has occupied the field of drug safety regulation by 
pervasively and comprehensively regulating the labeling and advertising of contracep-
tive drugs. The FDA's regulations, Upjohn may further argue, require that extensive 
information be included in Depo-Provera's labeling and that the drug's consumer ad-
vertising be written in compliance with Section 502(n). Courts, however, would be 
reluctant to infer preemption from the comprehensiveness of the FDCA and FDA regu-
•s See 21 U.S.C. § 352(n). 
46 Richard Ausness, Federal Preemption of State Products Liability Doctrines, 44 S.C. L. REv. 187, 
193 (1993). 
47 See Hillsborough County v. Automated Med. Labs., 471 U.S. 7fJ7, 714 (1985). 
48 See Noah, supra note 20, at 351-61. See also Brian Donato & Mary Beth Neraas, Federal Preemp-
tion of Product Liability Claims Involving Drugs and Medical Devices Regulated Under the Federal Food, 
Drug, and Cosmetic Act, 45 Fooo DRUG CosM. L.J. 305,317 (1993). 
49 Hillsborough, 471 U.S. at 714. 
so /d. at 707. 
51 /d. at 716. 
52 844 F.2d 1108 (4th Cir. 1988). 
53 742 F. Supp. 239 (E.D. Pa. 1990). 
54 /d. at 246. 
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lations, because that would be "tantamount to saying that whenever a federal agency 
decides to step into a field, its regulation will be exclusive."55 Courts would, therefore, 
be likely to follow Spychala v. Searle, which held that federal regulation did not pre-
empt state tort law unless there was "statutory or regulatory language or legislative 
history that lends support to the conclusion that Congress intended to exclude state tort 
law."56 
In the case of section 502(n), neither its language nor its legislative history suggest 
that Congress, in granting the FDA authority to regulate prescription drug advertising, 
intended to preempt state tort law. If a court examined the FDA's section 502(n) claim 
of authority to regulate prescription drug advertisements irrespective of their audience, 57 
it would find that for the first twenty years, the FDA limited its section 502(n) regula-
tion to advertisements directed at physicians. In 1983, however, the agency responded 
to drug company plans to advertise their prescription drug products to the public by 
I 
calling for a temporary moratorium to discuss and study the subject. 58 Two years later, 
the FDA withdrew the memorandum and stated in a Federal Register announcement 
that it would "continue to regulate prescription drug advertising regardless of audience 
in accordance with section 502(n)."59 
A court could find that the FDA's extension of section 502(n) to direct-to-con-
sumer advertisements is unsupported by the statute's legislative history and the contem-
poraneous comments by FDA administrators, which suggest that section 502(n) was 
enacted "to provide physicians with better and more adequate infonnation about drugs."60 
Moreover, the FDA's request for a moratorium in 1983 did not follow the Administra-
tive Procedure Act's (APA's) notice-and-comment rulemaking procedures,61 nor those 
of FDCA section 701(e).62 In fact, the FDA's 1985 Federal Register announcement 
withdrawing the moratorium is legally problematic, because the agency "merely re-
ported its decision to regulate direct-to-consumer advertising under section 502(n)."63 
Since federal appellate courts have been willing to strike down the FDA's extension of 
regulations to related, but new, areas without following infonnal rulemaking proce-
dures, 64 it is quite possible to "foresee a situation where the agency's attempt to regulate 
direct-to-consumer advertising under section 502(n) ... is legally challenged and ad-
judged improper."65 Even if a federal court resolves this issue and requires the FDA to 
follow APA infonnal rulemaking procedures in regulating of consumer-directed pre-
scription drug advertisements, state product liability law will continue to provide a 
critical drug risk regulation mechanism for the consumer, because Congress did not 
intend to preempt state tort law when it enacted section 502. 
Upjohn also may argue that there is an actual conflict between state product liabil-
ity law and section 502(n) on frustration of federal purpose grounds. The company 
could claim that a state product liability damage award based on the drug's failure to 
55 Hillsborough, 471 U.S. at 716. 
s.s 705 F. Supp. 1024, 1030 (D.N.J. 1988). 
57 See Gilgore, supra note 10, at 850. 
58 FDA Statement of Policy: Direct-to-Consumer Advertising of Prescription Drugs, Moratorium and 
Cover Letter (Sept. 2, 1983). See also Novitch, supra note 10, at 306; SO Fed. Reg. at 36,677. 
59 SO Fed. Reg. at 36,677. 
60 S. Rep. No. 1744, 87th Cong., 2d Sess. 33 (1962) (views of Sen. Kefauver). 
61 See 5 U.S.C. §§ 551-559, 701-706 (1988 and Supp. 1993). 
62 21 U.S.C. § 371(e). 
63 Schwartz, supra note 33, at 857. 
64 /d. 
65 /d. at 858. 
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warn about heavy and prolonged menstrual bleeding conflicts with the FDA's finding of 
an adequate warning, thereby frustrating the agency's effective communication of the 
drug's labeling to physicians. A Depo-Provera advertisement written in compliance 
with section 502(n), Upjohn may argue further, could expose the company to poten-
tially ruinous state product liability for its failure to adequately disclose the drug's risks. 
To provide a more inclusive warning, Upjohn might suggest, would produce an adver-
tisement so overloaded with information that it might fail to adequately inform consum-
ers. 
Upjohn is likely to be disappointed by the judicial response to this argument. Courts 
have not been persuaded by frustration of federal purpose arguments, and would be 
likely to respond, as the Supreme Court did in Hillsborough County and as the federal 
courts did in Abbott and Mazur, by rejecting the argument that FDA regulations have 
not struck a balance between drug safety and availability. Instead, these courts have 
decided that the agency's labeling regulations merely establish minimum standards and 
allow the states to strike a balance by supplementing federal regulations.66 As the Mazur 
court recognized, federal regulation and state tort law serve distinct purposes. "Essen-
tially, federal regulation serves a deterrent purpose by limiting the manufacture of in-
herently dangerous products to those applicants whp meet certain stringent safety stan-
dards, while state tort law serves the equally important purpose of compensating indi-
viduals injured by those very same products."67 Together, they create a dual system of 
drug risk management in which "compliance with FDA regulations will not ensure that 
a manufacturer's products will not cause injury ... [and w]hen those products do cause 
injuries, the state tort system provides a means of compensation.68 
Since Depo-Provera's labeling does not effectively communicate to physicians the 
significance of the Schwallie and Assenzo findings of prolonged menstrual bleeding, a 
court could find that state product liability law is "free to demand more" so that physi-
cians can act as learned intermediaries.69 It would be a small step for a court to reason 
that section 502(n)'s extension to consumer-directed advertising in 1985 has made the 
role of product liability law in the dual system of drug risk management even more 
important. In the case of Depo-Provera, a court could find that the consumer-directed 
advertisement and its accompanying patient information are not adequate for the pur-
pose of informing women because the advertisement does not mention the Schwallie 
and Assenzo findings and because the patient information misrepresents the findings by 
saying that heavy and prolonged menstrual bleeding is not a usual effect.'0 As a conse-
quence, a more detailed advertisement would lead not to information overload, but to 
the disclosure of one significant side effect (heavy and prolonged menstrual bleeding) 
that would allow a woman to make an informed contraceptive choice. 
E. Depo-Provera s Product Liability in the Hypothetical Case 
Assuming that a court rejects U pjohn 's learned intermediary and preemption argu-
ments in the hypothetical case , the outcome of the litigation will be governed by state 
product liability law. Here the issue will be whether the warnings about Depo-Provera 
66 Mazur, 742 F. Supp. at 247. 
67 /d. 
68 Richard Cooper, Drug Labeling and Products Liability: The Role of the Food and Drug Adminis-
tration, 41 Fooo DRUG CosM. L.J. 233,235 (1986). 
69 Schwallie & Assenzo, supra note 14. 
70 See Upjohn advertisement, supra note 11. 
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contained in the advertisement are adequate for the average woman consumer. Adopt-
ing this general legal standard, there are several questions the attorney for the woman in 
our hypothetical case would ask about the Depo-Provera advertisement: Are the warn-
ings about excessive and prolonged menstrual bleeding prominently displayed in the 
advertisement? Are the warnings easy to understand or are they detailed in small type 
and technical language? If the warnings are not in the advertisement, are they contained 
on a separate page and easy to understand? A trial jury's answers will determine whether 
Upjohn has met its obligation adequately to inform the consumer that Depo-Provera 
can cause heavy and prolonged menstrual bleeding in 26.9% of women during the first 
three months of use. 
In the Depo-Provera advertisement, menstrual bleeding is the first of four side 
effects identified under the heading "Some of the side effects of Depo-Pro vera. "71 In the 
same type as all the other drug information, it states: "Most women experience irregular 
and unpredictable menstrual bleeding."72 There is no other reference to menstrual bleed· 
ing in the advertisement, nor does the advertisement specifically state that there is more 
detail about this warning on the next page. It merely states: "Please read the accompa-
nying patient information and discuss it with your physician."73 
In the patient information, a bold heading,jdentical to the other nine headings, asks 
"What are the Risks of Using Depo-Provera Contraceptive Injection?" Irregular men-
strual bleeding, as listed in the advertisement, is the first side effect identified. In small 
type, identical to the other patient information, the following explanation is provided: 
The side effect reported most frequently by women who use DEPO-PROVERA 
for contraception is a change in their normal menstrual cycle. During the first 
year of using DEPO-PROVERA, you might have one or more of the following 
changes: Irregular or unpredictable bleeding or spotting, an increase or de-
crease in menstrual bleeding, or no bleeding at all. Unusually heavy or con-
tinuous bleeding, however, is not a usual effect of DEPO-PROVERA, and if 
this happens, you should see your health care provider right away.74 
No other information is given about heavy and continuous menstrual bleeding under 
this heading or in the remainder of the patient information. If a woman called the 800 
number, the brochure would provide the same brief statement about irregular and un-
predictable menstrual bleeding and the patient labeling would provide a statement iden-
tical to the one in the patient information. A physician is provided with no more sub-
stantial information. The Upjohn physician information states under the heading Bleed-
ing Irregularities: ''DEPO-PROVERA Contraceptive injection disrupts menstrual bleed-
ing patterns in most women, irregular or unpredictable bleeding or spotting or, rarely, 
heavy or continuous bleeding may occur."75 This statement is taken almost verbatim 
from the PDR.16 In its reference section, the PDR cites the 1973 Fertility and Sterility 
article by Schwallie and Assenzo, but the article's title, "Contraceptive Use-Efficacy 
Study Utilizing Medroxyprogesterone Acetate Administered as an Intramuscular Injec-





75 See supra note 29. 
76 See PDR, supra note 30, at 2544. 
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bleeding.n 
Neither the Depo-Provera advertisement nor the 800 number brochure makes any 
reference to heavy and prolonged menstrual bleeding. The patient information accom-
panying the advertisement and the patient labeling from the 800 number materials state 
only that "heavy or continuous bleeding is not a usual effect. "78 Even the physician 
advertisement and the PDR characterize this bleeding as a rare occurrence. None of 
these materials discloses the Schwallie and Assenzo findings about severe bleeding. It 
seems clear that Upjohn has known for twenty years that Depo-Provera causes severe 
menstrual bleeding, yet the company did not inform physicians about this side effect 
when it wrote the drug's 1974 package insert. In 1986, a Florida trial jury found Upjohn 
negligent for its failure to warn Anne MacMurdo's physician about the prospect of 
heavy and continuous bleeding. In its Depo-Provera labeling and subsequent drug ad-
vertisement, the company did not disclose the Schwallie and Assenzo findings. 
If, therefore, the woman in this article's hypothetical case read the Depo-Provera 
advertisement, the accompanying patient information, and the 800 number materials, 
and then visited her physician and received an injection for contraception, she should 
be able to prove that Upjohn negligently failed to warn her that the drug causes heavy 
and prolonged menstrual bleeding, and that she made an uninformed decision to her 
detriment. But if she wishes to prevail in her product liability suit, she also will have to 
establish not only that the warning was inadequate, but that it caused her injury. On the 
issue of causation, Upjohn would not be able to claim that the physician had "the op-
portunity to provide the patient with information about the prescription product, and, 
thereby, break the causal link between manufacturer's failure to warn and the patient's 
injury."79 Allowing this defense would reinstate the learned intermediary rule. If, how-
ever, "a doctor actually provides a plaintiff with information missing from the adver-
tisement, then the causal chain is broken by the doctor and the plaintiff should not 
recover."80 Given the absence in the Upjohn physician advertising material and the 
PDR information on severe menstrual bleeding, it is unlikely that a physician would 
have been able to supply the additional drug labeling information. 
IV. CONCLUSION 
Prescription drugs have been advertised directly to the public for over a decade. 
The Upjohn consumer advertisement for Depo-Provera has provided the opportunity to 
raise several questions about the FDA's authority over advertising. FDCA section 502(n) 
grants the FDA authority to regulate advertisements to physicians, but the agency's 
authority to regulate consumer-directed prescription drugs is legally questionable, and 
its judicial disposition uncertain. Until this issue is decided, the Depo-Provera adver-
tisement appears to comply with section 502{n)'s brief summary requirement and may 
fairly represent the drug's benefits. Whether the advertisement fairly represents the 
drug's risks has been the focus of this analysis. 
The Depo-Provera advertisement, it has been argued, could expose Upjohn to state 
product liability suits because the advertisement does not disclose, for example, one 
serious short-term side effect: heavy and prolonged menstrual bleeding. In a product 
liability suit, the company might raise the learned intermediary defense, but that de-
77 /d. at 2545. See also Schwallie & Assenzo, supra note 14. 
"' See Schwartz, supra note 33, at 847 (emphasis in original). 
19 /d. (emphasis added). 
80 See Schwartz, supra note 33, at 848 (emphasis added). 
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fense may fail if a court were willing to extend the contraceptive exception or create a 
new advertising exception to the learned intermediary rule. Even if a court were unwill-
ing to extend the contraceptive exception or create an advertising exception, it would 
be likely to reject Upjohn's claim that the FDCA preempts state product liability claims. 
As a consequence this analysis suggests that the woman in the hypothetical case is 
likely to prove that Upjohn negligently failed to warn her about the drug's risks. 
In sum, this article has examined the FDA's regulation of consumer-oriented pre-
scription drug advertising within the wider context of the agency's participation in a 
dual system of risk regulation. This study casts some doubt on the argument that the 
courts and state product liability law do not have a prominent risk regulation role and 
that drug risk regulation ought to be the sole providence of the FDA. In fact, this analy-
sis suggests that the current dual system provides for a comprehensive approach to risk 
reduction in which the FDA's regulatory process uses scientific experts to conduct an ex 
ante probabilistic evaluation of a drug's benefits versus risks, and a judicial regulatory 
process relies on state trial judges and lay juries who focus on a drug's ex facto risks in 
determining whether that drug caused the adverse event. 81 
81 See Grabowski, supra note 3, at 361-64. 

